{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:37:08Z","timestamp":1789835828629,"version":"4.0.1"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2021.07854"],"award-info":[{"award-number":["2021.07854"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["REPAIR - PL23-00001"],"award-info":[{"award-number":["REPAIR - PL23-00001"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regenerative Therapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.reth.2025.10.020","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:24:29Z","timestamp":1762313069000},"page":"1024-1035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Mesenchymal stem cells in neurological disorders: Insights from clinical trials"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2181-2203","authenticated-orcid":false,"given":"Beatriz","family":"Ara\u00fajo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-1599","authenticated-orcid":false,"given":"In\u00eas","family":"Serrenho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia","family":"Valente da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3456-6655","authenticated-orcid":false,"given":"Bragan\u00e7a Mois\u00e9s","family":"Marceta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gra\u00e7a","family":"Baltazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.reth.2025.10.020_bib1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3109\/14653249.2010.549122","article-title":"Comparison of mesenchymal stem cells from adipose tissue and bone marrow for ischemic stroke therapy","volume":"13","author":"Ikegame","year":"2011","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.reth.2025.10.020_bib2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.15283\/ijsc18034","article-title":"Mesenchymal stem cells from the wharton's jelly of the human umbilical cord: biological properties and therapeutic potential","volume":"12","author":"Marino","year":"2019","journal-title":"Int J Stem Cells"},{"key":"10.1016\/j.reth.2025.10.020_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.21037\/sci.2019.08.11","article-title":"A revealing review of mesenchymal stem cells therapy, clinical perspectives and modification strategies","volume":"6","author":"Saeedi","year":"2019","journal-title":"Stem Cell Invest"},{"issue":"4","key":"10.1016\/j.reth.2025.10.020_bib4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"issue":"10","key":"10.1016\/j.reth.2025.10.020_bib5","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/sctm.19-0430","article-title":"Mesenchymal stem cells as a multimodal treatment for nervous system diseases","volume":"9","author":"Badyra","year":"2020","journal-title":"Stem Cells Transl Med"},{"issue":"10","key":"10.1016\/j.reth.2025.10.020_bib6","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1007\/s12035-022-02967-4","article-title":"Paracrine effects of mesenchymal stem cells in ischemic stroke: opportunities and challenges","volume":"59","author":"Asgari","year":"2022","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.reth.2025.10.020_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13578-020-00475-3","article-title":"Treatment of spinal cord injury with mesenchymal stem cells","volume":"10","author":"Liau","year":"2020","journal-title":"Cell Biosci"},{"key":"10.1016\/j.reth.2025.10.020_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.650664","article-title":"The current status of mesenchymal stromal cells: controversies, unresolved issues and some promising solutions to improve their therapeutic efficacy","volume":"9","author":"Garc\u00eda-Bernal","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13578-021-00698-y","article-title":"Allogeneic vs. autologous mesenchymal stem\/stromal cells in their medication practice","volume":"11","author":"Li","year":"2021","journal-title":"Cell Biosci"},{"issue":"19","key":"10.1016\/j.reth.2025.10.020_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911453","article-title":"Stem cells in clinical trials on neurological disorders: trends in stem cells origins, indications, and status of the clinical trials","volume":"23","author":"Namiot","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13287-018-0914-1","article-title":"Adipose-derived and bone marrow mesenchymal stem cells: a donor-matched comparison","volume":"9","author":"Mohamed-Ahmed","year":"2018","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"10.1016\/j.reth.2025.10.020_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/scrt442","article-title":"Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton's jelly","volume":"5","author":"Amable","year":"2014","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"10.1016\/j.reth.2025.10.020_bib13","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1007\/s12015-021-10157-3","article-title":"Mesenchymal stromal cells from different parts of umbilical cord: approach to comparison & characteristics","volume":"17","author":"Semenova","year":"2021","journal-title":"Stem Cell Rev Rep"},{"issue":"3","key":"10.1016\/j.reth.2025.10.020_bib14","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3892\/ijmm.2014.1821","article-title":"Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation","volume":"34","author":"Li","year":"2014","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.reth.2025.10.020_bib15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13287-016-0295-2","article-title":"Human bone marrow-derived and umbilical cord-derived mesenchymal stem cells for alleviating neuropathic pain in a spinal cord injury model","volume":"7","author":"Yousefifard","year":"2016","journal-title":"Stem Cell Res Ther"},{"issue":"14","key":"10.1016\/j.reth.2025.10.020_bib16","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1089\/scd.2013.0416","article-title":"The therapeutic effects of human adipose-derived stem cells in a rat cervical spinal cord injury model","volume":"23","author":"Kolar","year":"2014","journal-title":"Stem Cell Dev"},{"issue":"4","key":"10.1016\/j.reth.2025.10.020_bib17","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jcyt.2012.11.015","article-title":"Comparison of mesenchymal stromal cells from human bone marrow and adipose tissue for the treatment of spinal cord injury","volume":"15","author":"Zhou","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.reth.2025.10.020_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.615508","article-title":"A review of placenta and umbilical cord-derived stem cells and the immunomodulatory basis of their therapeutic potential in bronchopulmonary dysplasia","volume":"9","author":"Chia","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.reth.2025.10.020_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.neulet.2013.03.018","article-title":"Comparison of cell proliferation, apoptosis, cellular morphology and ultrastructure between human umbilical cord and placenta-derived mesenchymal stem cells","volume":"541","author":"Zhu","year":"2013","journal-title":"Neurosci Lett"},{"issue":"5","key":"10.1016\/j.reth.2025.10.020_bib20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jcyt.2017.03.001","article-title":"Comparison of human mesenchymal stromal cells from four neonatal tissues: amniotic membrane, chorionic membrane, placental decidua and umbilical cord","volume":"19","author":"Ara\u00fajo","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.reth.2025.10.020_bib21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1741-7015-11-146","article-title":"Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells","volume":"11","author":"Siegel","year":"2013","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.reth.2025.10.020_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cells11060946","article-title":"Batch effects during human bone marrow stromal cell propagation prevail donor variation and culture duration: impact on genotype, phenotype and function","volume":"11","author":"Brachtl","year":"2022","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.reth.2025.10.020_bib23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/(SICI)1097-4644(19991201)75:3<424::AID-JCB8>3.0.CO;2-8","article-title":"Donor variation in the growth properties and osteogenic potential of human marrow stromal cells","volume":"75","author":"Phinney","year":"1999","journal-title":"J Cell Biochem"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.brainres.2004.11.055","article-title":"Axon growth and recovery of function supported by human bone marrow stromal cells in the injured spinal cord exhibit donor variations","volume":"1035","author":"Neuhuber","year":"2005","journal-title":"Brain Res"},{"key":"10.1016\/j.reth.2025.10.020_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.624601","article-title":"Consistent long-term therapeutic efficacy of human umbilical cord matrix-derived mesenchymal stromal cells after myocardial infarction despite individual differences and transient engraftment","volume":"9","author":"Laundos","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.reth.2025.10.020_bib26","series-title":"Effect of mesenchymal stem cells transfusion on the diabetic peripheral neuropathy patients","author":"Saadi","year":"2018"},{"key":"10.1016\/j.reth.2025.10.020_bib27","series-title":"Safety study of local administration of autologous bone marrow stromal cells in chronic paraplegia (CME-LEM1)","author":"Vaquero Crespo","year":"2019"},{"key":"10.1016\/j.reth.2025.10.020_bib28","series-title":"Repeated subarachnoid administrations of hUC-MSCs in treating SCI","author":"Li Rong","year":"2020"},{"key":"10.1016\/j.reth.2025.10.020_bib29","series-title":"A study to evaluate the safety and efficacy of AstroStem in treatment of alzheimer's disease","year":"2021"},{"key":"10.1016\/j.reth.2025.10.020_bib30","series-title":"A study of UCB and MSCs in children with CP: accent-cp (ACCeNT-CP)","author":"Kurtzberg","year":"2021"},{"key":"10.1016\/j.reth.2025.10.020_bib31","series-title":"Safety and effectiveness of banked cord blood or bone marrow stem cells in children with cerebral Palsy","author":"Cox","year":"2022"},{"issue":"7","key":"10.1016\/j.reth.2025.10.020_bib32","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/TP.0b013e3182298a15","article-title":"Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study","volume":"92","author":"Orozco","year":"2011","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.reth.2025.10.020_bib33","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1474-4422(22)00117-X","article-title":"Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study","volume":"21","author":"Baak","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.reth.2025.10.020_bib34","series-title":"Study of allogeneic umbilical cord blood infusion for adults with ischemic stroke","author":"Kurtzberg","year":"2022"},{"key":"10.1016\/j.reth.2025.10.020_bib35","series-title":"Study of modified stem cells (SB623) in patients with chronic motor deficit from ischemic stroke","author":"Steinberg","year":"2020"},{"issue":"9","key":"10.1016\/j.reth.2025.10.020_bib36","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1080\/14737175.2021.1968299","article-title":"Determining minimally clinically important differences for outcome measures in patients with chronic motor deficits secondary to traumatic brain injury","volume":"21","author":"McCrea","year":"2021","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.reth.2025.10.020_bib37","series-title":"Randomized, double-blind clinical trial for Parkinson's disease (early and moderate)","author":"Lotfi","year":"2024"},{"key":"10.1016\/j.reth.2025.10.020_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.brainres.2013.08.016","article-title":"Transplantation of autologous bone marrow mesenchymal stem cells in the treatment of complete and chronic cervical spinal cord injury","volume":"1533","author":"Dai","year":"2013","journal-title":"Brain Res"},{"key":"10.1016\/j.reth.2025.10.020_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/09636897221083863","article-title":"Final results of allogeneic adipose tissue-derived mesenchymal stem cells in acute ischemic stroke (AMASCIS): a phase II, randomized, double-blind, placebo-controlled, single-center, pilot clinical trial","volume":"31","author":"de Celis-Ruiz","year":"2022","journal-title":"Cell Transplant"},{"issue":"Pt 6","key":"10.1016\/j.reth.2025.10.020_bib40","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/brain\/awr063","article-title":"Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke","volume":"134","author":"Honmou","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.reth.2025.10.020_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2021.106565","article-title":"Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series","volume":"203","author":"Honmou","year":"2021","journal-title":"Clin Neurol Neurosurg"},{"issue":"12","key":"10.1016\/j.reth.2025.10.020_bib42","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.3727\/096368912X658818","article-title":"Feasibility of delivering mesenchymal stem cells via catheter to the proximal end of the lesion artery in patients with stroke in the territory of the middle cerebral artery","volume":"22","author":"Jiang","year":"2013","journal-title":"Cell Transplant"},{"issue":"4","key":"10.1016\/j.reth.2025.10.020_bib43","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/sj.bmt.1703650","article-title":"Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH)","volume":"30","author":"Ko\u00e7","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.reth.2025.10.020_bib44","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jcyt.2021.03.005","article-title":"The effects of intravenous infusion of autologous mesenchymal stromal cells in patients with subacute middle cerebral artery infarct: a phase 2 randomized controlled trial on safety, tolerability and efficacy","volume":"23","author":"Law","year":"2021","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.reth.2025.10.020_bib45","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1179\/016164106X116791","article-title":"Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis","volume":"28","author":"Mazzini","year":"2006","journal-title":"Neurol Res"},{"issue":"6","key":"10.1016\/j.reth.2025.10.020_bib46","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/scrt516","article-title":"Safety and neurological assessments after autologous transplantation of bone marrow mesenchymal stem cells in subjects with chronic spinal cord injury","volume":"5","author":"Mendon\u00e7a","year":"2014","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"10.1016\/j.reth.2025.10.020_bib47","first-page":"155","article-title":"FOXP3 gene expression in multiple sclerosis patients pre- and post mesenchymal stem cell therapy","volume":"10","author":"Mohajeri","year":"2011","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib48","first-page":"50","article-title":"Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study","volume":"4","author":"Mohyeddin Bonab","year":"2007","journal-title":"Iran J Immunol"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41393-021-00687-5","article-title":"Safety and feasibility of autologous olfactory ensheathing cell and bone marrow mesenchymal stem cell co-transplantation in chronic human spinal cord injury: a clinical trial","volume":"60","author":"Zamani","year":"2022","journal-title":"Spinal Cord"},{"issue":"12","key":"10.1016\/j.reth.2025.10.020_bib50","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/sctm.17-0219","article-title":"Mesenchymal stem cells for severe intraventricular hemorrhage in preterm infants: phase I dose-escalation clinical trial","volume":"7","author":"Ahn","year":"2018","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000333381","article-title":"Autologous mesenchymal stem cells in chronic stroke","volume":"1","author":"Bhasin","year":"2011","journal-title":"Cerebrovasc Dis Extra"},{"issue":"2","key":"10.1016\/j.reth.2025.10.020_bib52","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.mayocp.2019.10.008","article-title":"CELLTOP clinical trial: first report from a phase 1 trial of autologous adipose tissue-derived mesenchymal stem cells in the treatment of paralysis due to traumatic spinal cord injury","volume":"95","author":"Bydon","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib53","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1038\/s41467-024-46259-y","article-title":"Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: phase I trial","volume":"15","author":"Bydon","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib54","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12967-016-0880-2","article-title":"Finding a new therapeutic approach for no-option parkinsonisms: mesenchymal stromal cells for progressive supranuclear palsy","volume":"14","author":"Canesi","year":"2016","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.reth.2025.10.020_bib55","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458517703802","article-title":"Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis","volume":"24","author":"Cohen","year":"2018","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.reth.2025.10.020_bib56","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/cns.12559","article-title":"Impact of autologous mesenchymal stem cell infusion on neuromyelitis optica spectrum disorder: a pilot, 2-Year observational study","volume":"22","author":"Fu","year":"2016","journal-title":"CNS Neurosci Ther"},{"issue":"12","key":"10.1016\/j.reth.2025.10.020_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8122102","article-title":"Short and long term clinical and immunologic follow up after bone marrow mesenchymal stromal cell therapy in progressive multiple Sclerosis-A phase I study","volume":"8","author":"Iacobaeus","year":"2019","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.reth.2025.10.020_bib58","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s12975-020-00787-z","article-title":"Autologous mesenchymal stem cells improve motor recovery in subacute ischemic stroke: a randomized clinical trial","volume":"11","author":"Jaillard","year":"2020","journal-title":"Transl Stroke Res"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib59","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3892\/etm.2013.1083","article-title":"A clinical trial report of autologous bone marrow-derived mesenchymal stem cell transplantation in patients with spinal cord injury","volume":"6","author":"Jiang","year":"2013","journal-title":"Exp Ther Med"},{"issue":"2","key":"10.1016\/j.reth.2025.10.020_bib60","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.trci.2015.06.007","article-title":"Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with alzheimer's disease dementia: a phase 1 clinical trial","volume":"1","author":"Kim","year":"2015","journal-title":"Alzheimer's Dement"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib61","article-title":"Feasibility of mesenchymal stem cell culture expansion for a phase I clinical trial in multiple sclerosis","volume":"4","author":"Planchon","year":"2018","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib62","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.expneurol.2009.08.007","article-title":"Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a phase I clinical trial","volume":"223","author":"Mazzini","year":"2010","journal-title":"Exp Neurol"},{"issue":"6","key":"10.1016\/j.reth.2025.10.020_bib63","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/ana.20501","article-title":"Autologous mesenchymal stem cell transplantation in stroke patients","volume":"57","author":"Bang","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.reth.2025.10.020_bib64","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12967-014-0253-7","article-title":"Clinical observation of umbilical cord mesenchymal stem cell transplantation in treatment for sequelae of thoracolumbar spinal cord injury","volume":"12","author":"Cheng","year":"2014","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib65","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/13524585221122156","article-title":"Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis","volume":"29","author":"Cohen","year":"2023","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.reth.2025.10.020_bib66","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/stcltm\/szad027","article-title":"A pilot phase I trial of allogeneic umbilical cord tissue-derived mesenchymal stromal cells in neonates with hypoxic-ischemic encephalopathy","volume":"12","author":"Cotten","year":"2023","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib67","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10072-021-05291-2","article-title":"An open-label phase 1 clinical trial of the allogeneic side population adipose-derived mesenchymal stem cells in SMA type 1 patients","volume":"43","author":"Mohseni","year":"2022","journal-title":"Neurol Sci"},{"issue":"6","key":"10.1016\/j.reth.2025.10.020_bib68","doi-asserted-by":"crossref","first-page":"590","DOI":"10.5966\/sctm.2014-0212","article-title":"Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis","volume":"4","author":"Oh","year":"2015","journal-title":"Stem Cells Transl Med"},{"issue":"3","key":"10.1016\/j.reth.2025.10.020_bib69","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1227\/NEU.0000000000001056","article-title":"A phase III clinical trial showing limited efficacy of autologous mesenchymal stem cell therapy for spinal cord injury","volume":"78","author":"Oh","year":"2016","journal-title":"Neurosurgery"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib70","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12967-018-1433-7","article-title":"Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis","volume":"16","author":"Riordan","year":"2018","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib71","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1212\/WNL.0000000000007720","article-title":"Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy","volume":"93","author":"Singer","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.reth.2025.10.020_bib72","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jcyt.2018.03.032","article-title":"Intrathecal administration of autologous mesenchymal stromal cells for spinal cord injury: safety and efficacy of the 100\/3 guideline","volume":"20","author":"Vaquero","year":"2018","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/j.reth.2025.10.020_bib73","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jcyt.2016.12.002","article-title":"Repeated subarachnoid administrations of autologous mesenchymal stromal cells supported in autologous plasma improve quality of life in patients suffering incomplete spinal cord injury","volume":"19","author":"Vaquero","year":"2017","journal-title":"Cytotherapy"},{"issue":"6","key":"10.1016\/j.reth.2025.10.020_bib74","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1179\/2045772315Y.0000000048","article-title":"Intrathecal transplantation of autologous adipose-derived mesenchymal stem cells for treating spinal cord injury: a human trial","volume":"39","author":"Hur","year":"2016","journal-title":"J Spinal Cord Med"},{"key":"10.1016\/j.reth.2025.10.020_bib75","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.brainres.2013.08.001","article-title":"Umbilical cord mesenchymal stem cell transplantation significantly improves neurological function in patients with sequelae of traumatic brain injury","volume":"1532","author":"Wang","year":"2013","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib76","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13287-019-1545-x","article-title":"Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial","volume":"11","author":"Gu","year":"2020","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"10.1016\/j.reth.2025.10.020_bib77","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.msard.2014.08.002","article-title":"Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study","volume":"3","author":"Lublin","year":"2014","journal-title":"Mult Scler Relat Disord"},{"issue":"21","key":"10.1016\/j.reth.2025.10.020_bib78","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000003359","article-title":"Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS","volume":"87","author":"Staff","year":"2016","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.reth.2025.10.020_bib79","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/sctm.19-0434","article-title":"Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder","volume":"9","author":"Sun","year":"2020","journal-title":"Stem Cells Transl Med"},{"issue":"8","key":"10.1016\/j.reth.2025.10.020_bib80","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4252\/wjsc.v9.i8.133","article-title":"Phase I\/II randomized controlled trial of autologous bone marrow-derived mesenchymal stem cell therapy for chronic stroke","volume":"9","author":"Tsang","year":"2017","journal-title":"World J Stem Cell"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib81","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcyt.2020.09.012","article-title":"Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: a phase 1\/2 pilot study","volume":"23","author":"Yang","year":"2021","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib82","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/156720213804805936","article-title":"Safety and efficacy of umbilical cord mesenchymal stem cell therapy in hereditary spinocerebellar ataxia","volume":"10","author":"Jin","year":"2013","journal-title":"Curr Neurovascular Res"},{"issue":"10","key":"10.1016\/j.reth.2025.10.020_bib83","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archneurol.2010.248","article-title":"Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis","volume":"67","author":"Karussis","year":"2010","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.reth.2025.10.020_bib84","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/14653240701883061","article-title":"A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury","volume":"10","author":"Zhang","year":"2008","journal-title":"Cytotherapy"},{"issue":"12","key":"10.1016\/j.reth.2025.10.020_bib85","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1093\/brain\/awaa333","article-title":"Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis","volume":"143","author":"Petrou","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.reth.2025.10.020_bib86","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.reth.2021.07.006","article-title":"Safety and efficacy of bone marrow derived-mesenchymal stem cells transplantation in patients with amyotrophic lateral sclerosis","volume":"18","author":"Tavakol-Afshari","year":"2021","journal-title":"Regen Ther"},{"issue":"5","key":"10.1016\/j.reth.2025.10.020_bib87","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/sj.clpt.6100386","article-title":"Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy","volume":"83","author":"Lee","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib88","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ana.23612","article-title":"A randomized trial of mesenchymal stem cells in multiple system atrophy","volume":"72","author":"Lee","year":"2012","journal-title":"Ann Neurol"},{"issue":"24","key":"10.1016\/j.reth.2025.10.020_bib89","doi-asserted-by":"crossref","first-page":"e2294","DOI":"10.1212\/WNL.0000000000008620","article-title":"NurOwn, phase 2, randomized, clinical trial in patients with ALS: safety, clinical, and biomarker results","volume":"93","author":"Berry","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib90","doi-asserted-by":"crossref","first-page":"14","DOI":"10.46582\/jsrm.1301003","article-title":"Safety and feasibility of autologous mesenchymal stem cell Transplantation in Chronic stroke in Indian patients. A four-year follow up","volume":"13","author":"Bhasin","year":"2017","journal-title":"J Stem Cells Regen Med"},{"issue":"4","key":"10.1016\/j.reth.2025.10.020_bib91","first-page":"592","article-title":"Safety, feasibility of intravenous and intrathecal injection of autologous bone marrow derived mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: an open label phase I clinical trial","volume":"20","author":"Nabavi","year":"2019","journal-title":"Cell J"},{"issue":"19","key":"10.1016\/j.reth.2025.10.020_bib92","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1182\/blood-2010-08-304287","article-title":"CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with in situ localization","volume":"117","author":"Tormin","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.reth.2025.10.020_bib93","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/stem.312","article-title":"In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment","volume":"28","author":"Russell","year":"2010","journal-title":"Stem Cell"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib94","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/jcmm.12168","article-title":"CD146 expression on mesenchymal stem cells is associated with their vascular smooth muscle commitment","volume":"18","author":"Espagnolle","year":"2014","journal-title":"J Cell Mol Med"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib95","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11373-007-9207-x","article-title":"Insulin-like growth factor 1 improves the efficacy of mesenchymal stem cells transplantation in a rat model of myocardial infarction","volume":"15","author":"Guo","year":"2008","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.reth.2025.10.020_bib96","article-title":"The roles of insulin-like growth factors in mesenchymal stem cell niche","volume":"2017","author":"Youssef","year":"2017","journal-title":"Stem Cell Int"},{"issue":"3","key":"10.1016\/j.reth.2025.10.020_bib97","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.stem.2008.07.003","article-title":"A perivascular origin for mesenchymal stem cells in multiple human organs","volume":"3","author":"Crisan","year":"2008","journal-title":"Cell Stem Cell"},{"issue":"10","key":"10.1016\/j.reth.2025.10.020_bib98","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1101\/gad.1653708","article-title":"Role of platelet-derived growth factors in physiology and medicine","volume":"22","author":"Andrae","year":"2008","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib99","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2249.2009.03874.x","article-title":"Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells","volume":"156","author":"English","year":"2009","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.reth.2025.10.020_bib100","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.4049\/jimmunol.1202996","article-title":"Prostaglandin E2 potentiates mesenchymal stem cell-induced IL-10+IFN-\u03b3+CD4+ regulatory T cells to control transplant arteriosclerosis","volume":"190","author":"Hsu","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.reth.2025.10.020_bib101","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.biomaterials.2015.11.005","article-title":"Mesenchymal stem cells engineered to express selectin ligands and IL-10 exert enhanced therapeutic efficacy in murine experimental autoimmune encephalomyelitis","volume":"77","author":"Liao","year":"2016","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.reth.2025.10.020_bib102","doi-asserted-by":"crossref","first-page":"879","DOI":"10.7150\/thno.87843","article-title":"Initial IL-10 production dominates the therapy of mesenchymal stem cell scaffold in spinal cord injury","volume":"14","author":"Yang","year":"2024","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.reth.2025.10.020_bib103","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s11658-022-00325-9","article-title":"Interleukin-10 genetically modified clinical-grade mesenchymal stromal cells markedly reinforced functional recovery after spinal cord injury via directing alternative activation of macrophages","volume":"27","author":"Gao","year":"2022","journal-title":"Cell Mol Biol Lett"},{"issue":"6","key":"10.1016\/j.reth.2025.10.020_bib104","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal stromal cells: clinical challenges and therapeutic opportunities","volume":"22","author":"Galipeau","year":"2018","journal-title":"Cell Stem Cell"}],"container-title":["Regenerative Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320425002172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320425002172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:23:25Z","timestamp":1778873005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352320425002172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":104,"alternative-id":["S2352320425002172"],"URL":"https:\/\/doi.org\/10.1016\/j.reth.2025.10.020","relation":{},"ISSN":["2352-3204"],"issn-type":[{"value":"2352-3204","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mesenchymal stem cells in neurological disorders: Insights from clinical trials","name":"articletitle","label":"Article Title"},{"value":"Regenerative Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reth.2025.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier BV on behalf of The Japanese Society for Regenerative Medicine.","name":"copyright","label":"Copyright"}]}}